New drug cocktail shows promise against tough pancreatic cancer
NCT ID NCT06266143
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumors. Results will show whether this approach is worth testing in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Y101D (an experimental drug) combined with gemcitabine and nab-paclitaxel (standard chemotherapy)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced pancreatic cancer, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is an early-phase trial with only 71 patients, so results may not apply broadly. The added drug Y101D could increase side effects without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- A sound wave that could expose hidden pancreatic cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?